Every Form 4 that Rockwell Medical, Inc. (DE) (RMTI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RMTI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RMTI filings page.
Dawson Joseph H reported acquisition or exercise transactions in this Form 4 filing.
Rockwell Medical director Joseph H. Dawson received an equity grant and his holdings were adjusted for a reverse split. On July 1, 2026, he was granted 9,633 shares in the form of restricted stock units at no cash cost. These units vest on July 1, 2027, if he continues serving through the 2027 annual meeting. Effective at 12:01 a.m. on July 1, 2026, Rockwell Medical completed a 1-for-10 reverse split of its common stock, and his existing shareholdings and equity awards were proportionately reduced. After giving effect to both the grant and the reverse split adjustments, Dawson beneficially owns 12,133 shares of common stock directly.
Nissenson Allen reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. director Allen Nissenson received a grant of 9,633 shares of Common Stock as a compensation award, recorded at a price of $0.0000 per share. These shares are in the form of restricted stock units that vest on July 1, 2027, subject to his continued service through the 2027 annual meeting.
The company also completed a 1-for-10 reverse split of its common stock effective 12:01 a.m. on July 1, 2026, which reduced the number of shares held and adjusted outstanding equity awards. After these changes and the grant, Nissenson beneficially owns 23,892 shares directly.
Lau Joan reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. director Joan Lau received a grant of 9,633 shares of Common Stock as a stock award, with no cash paid per share. These restricted stock units vest on July 1, 2027, subject to her continued service through the 2027 Annual Meeting. A 1-for-10 reverse split effective July 1, 2026 adjusted her holdings to 20,944 shares after the reported grant.
Radie Robert S reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. director Robert S. Radie received an award of 9,633 shares of common stock as a grant of restricted stock units, with no cash paid per share. Following this grant, he beneficially owns 23,985 shares directly.
The restricted stock units vest on July 1, 2027, subject to his continued service through the company’s 2027 annual meeting. The company also implemented a 1-for-10 reverse stock split effective July 1, 2026, and Radie’s reported shareholdings and equity awards have been adjusted to reflect this split.
COOPER JOHN G reported acquisition or exercise transactions in this Form 4 filing.
Rockwell Medical director John G. Cooper received an equity award rather than buying shares on the market. On July 1, 2026, he was granted 9,633 restricted stock units of common stock at no cash cost as compensation.
The RSUs vest on July 1, 2027, subject to his continued service through the 2027 Annual Meeting. Effective at 12:01 a.m. on July 1, 2026, Rockwell Medical implemented a 1-for-10 reverse stock split, and Cooper’s equity awards and holdings were proportionally adjusted. Following these adjustments and the reported grant, he beneficially owns 23,670 shares of common stock directly.
Chole Timothy reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. granted SVP and CCO Timothy Chole 15,000 shares of Common Stock as a compensation award, recorded at $0.00 per share. These restricted stock units vest in three equal installments on the first, second and third anniversaries of July 1, 2026, contingent on his continued service.
The company effected a 1-for-10 reverse split of its common stock effective at 12:01 AM on July 1, 2026. Following the grant and split adjustment, Chole beneficially owns 27,285 shares of Rockwell Medical common stock directly.
Hunter Heather reported acquisition or exercise transactions in this Form 4 filing.
Rockwell Medical Chief Operating Officer Heather Hunter reported receiving an award of 15,000 shares of common stock as compensation, at a stated price of $0.00 per share. Following this grant, she directly holds 28,007 shares of the company’s stock.
Footnotes explain that these are restricted stock units that vest in three equal installments on the first, second and third anniversaries of July 1, 2026, as long as she continues serving the company. The company also effected a 1-for-10 reverse stock split effective just after midnight on July 1, 2026, and her reported post-transaction holdings reflect this adjustment to both shares and outstanding equity awards.
TIMMINS MEGAN C. reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. executive Megan C. Timmins, EVP, CLO & Secretary, received a grant of 15,000 shares of common stock as restricted stock units at no cash cost. These RSUs vest in three equal installments on the first, second and third anniversaries of July 1, 2026, contingent on her continued service.
The filing also notes a 1-for-10 reverse stock split effective at 12:01 AM on July 1, 2026, which reduced her share count and adjusted outstanding equity awards. Following the grant and split adjustment, she beneficially owns 31,240 shares of common stock directly.
Neri Jesse reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. SVP and CFO Jesse Neri received a grant of 15,000 shares of common stock as a stock award, rather than an open-market purchase, at a stated price of $0.00 per share. These restricted stock units vest in three equal installments on the first, second and third anniversaries of July 1, 2026, subject to his continued service to the company.
Effective at 12:01 AM on July 1, 2026, the company completed a 1-for-10 reverse split of its common stock and adjusted outstanding equity awards. After reflecting both the reverse split and this award, Neri directly holds 27,239 shares of Rockwell Medical common stock.
Strobeck Mark reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. reported that President and CEO Mark Strobeck received an award of 30,000 shares of Common Stock as a grant, recorded at a price of $0.00 per share. Following this award, he directly beneficially owns 62,349 shares.
Footnotes explain that the award consists of restricted stock units that vest in three equal installments on the first, second and third anniversaries of July 1, 2026, subject to his continued service. The company also effected a 1-for-10 reverse stock split effective at 12:01 AM on July 1, 2026, which reduced the number of shares held and proportionately adjusted outstanding equity awards, with post-transaction holdings already reflecting this split.
Neri Jesse reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. reported that its SVP, Finance and CFO, Jesse Neri, received a grant of 97,500 performance-based restricted stock units (PSUs) on May 20, 2025. Each PSU represents the right to receive one share of common stock.
The PSUs have a three-year term ending on May 20, 2028. Any units that remain unvested at that third anniversary will be cancelled. Vesting can occur on or after the first anniversary of the grant date, but only if a performance hurdle is met.
The performance hurdle is satisfied if the average closing price of Rockwell Medical’s common stock over any 60 consecutive trading days during the three-year performance period equals two times the base price. The base price for this award is $2.14 per share. Following this grant, Neri holds 97,500 PSUs directly.
TIMMINS MEGAN C. reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. executive Megan C. Timmins, EVP, CLO and Secretary, received a grant of 97,500 performance-based restricted stock units (PSUs) tied to the company’s common stock. This is a compensation-related award, not an open-market stock purchase or sale.
The PSUs run for three years from the grant date and any unvested units are cancelled after the third anniversary. They can vest on or after the first anniversary only if a share-price performance hurdle is met over a 60-day trading window, using a base price of $2.14.
Chole Timothy reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. reported that SVP and Chief Commercial Officer Timothy Chole received a grant of 85,000 performance-based restricted stock units on May 20, 2025. Each unit relates to one share of common stock and was awarded at no cash cost.
The PSUs have a three-year term ending on the third anniversary of the grant date, with an expiration date of May 20, 2028. They vest on or after the first anniversary only if a stock-price performance hurdle is achieved.
The performance hurdle is met if the average closing price of Rockwell Medical’s common stock over any 60 consecutive trading days during the three-year performance period equals two times the base price. The base price for this award is $2.14, calculated from the average closing price over the ten trading days before the grant.
Strobeck Mark reported acquisition or exercise transactions in this Form 4 filing.
Rockwell Medical, Inc. reported that President and CEO Mark Strobeck received a grant of 352,000 performance-based restricted stock units (PSUs) tied to the company’s common stock. The PSUs have a three-year term from the May 20, 2025 grant date and expire on May 20, 2028.
The units vest only if a stock price performance hurdle is achieved. During the three-year performance period, the average closing price over any 60 consecutive trading days must reach two times the base price. The base price for this award is $2.14, calculated from the average closing price over the ten trading days before the grant date.
ROCKWELL MEDICAL, INC. Chief Operating Officer Heather Hunter reported a routine tax-related share disposition. On the vesting of restricted stock units, 2,444 shares of common stock were withheld at $0.90 per share to cover estimated tax obligations. After this withholding, she held 130,079 common shares directly.
ROCKWELL MEDICAL, INC. officer Megan C. Timmins reported a routine tax-related share disposition. On this Form 4, 3,667 shares of common stock were withheld at $0.90 per share to cover estimated tax obligations tied to the vesting of restricted stock units, rather than being sold on the market. After this withholding, Timmins directly holds 162,408 shares of Rockwell Medical common stock.
Rockwell Medical Senior Vice President and CFO Jesse Neri reported a routine tax-related share withholding. On the vesting of restricted stock units, 2,444 shares of common stock were withheld at $0.90 per share to cover estimated tax obligations. After this non-market disposition, Neri directly holds 122,398 shares of Rockwell Medical common stock.
ROCKWELL MEDICAL, INC. senior vice president and chief commercial officer Timothy Chole reported a routine tax-related share disposition. On the vesting of restricted stock units, 2,444 shares of common stock were withheld at $0.90 per share to cover estimated tax obligations. Following this withholding, he directly holds 122,855 shares of Rockwell Medical common stock.
ROCKWELL MEDICAL, INC. reported a routine tax-related share disposition by its President and CEO, Mark Strobeck. On the reported date, 7,333 shares of common stock were withheld in connection with the vesting of restricted stock units to cover estimated tax obligations, rather than being sold on the open market. Following this withholding, Strobeck directly owns 323,493 shares of Rockwell Medical common stock.
Rockwell Medical director reports new equity awards
A director of Rockwell Medical, Inc. (RMTI) reported receiving equity compensation on November 17, 2025. The filing shows an award of 25,000 shares of common stock, described as restricted stock units that vest on November 17, 2026, subject to continued service. After this grant, the director beneficially owns 25,000 common shares directly.
The director was also granted stock options for 25,000 shares of common stock at an exercise price of $0.87 per share, expiring on November 17, 2035. These options vest on November 17, 2026, also conditioned on continued service. The Form 4 notes that it is being filed late due to administrative delays in obtaining the director’s EDGAR codes.
Rockwell Medical, Inc. (RMTI) director John G. Cooper reported an open-market sale of company stock. On November 18, 2025, he sold 5,079 shares of Rockwell Medical common stock at a price of $0.87 per share, according to this Form 4 filing. After this transaction, Cooper beneficially owns 140,372 shares of Rockwell Medical common stock, held directly.
Insider sale under a trading plan: Senior Vice President and Chief Operating Officer Heather Hunter reported a sale of 2,868 shares of Rockwell Medical, Inc. (RMTI) on 10/01/2025 at a price of $1.19 per share, leaving her with 135,391 shares beneficially owned after the transaction. The filing states the sale was executed under a Rule 10b5-1 trading plan adopted on 12/13/2024, which creates an affirmative defense for scheduled insider trades.
The Form 4 was signed by an attorney-in-fact on 10/08/2025 and includes a remark that the filing is late due to administrative delays obtaining EDGAR codes. No derivative transactions or other non‑derivative purchases were reported on this form.
Insider sale under a 10b5-1 plan: Mark Strobeck, President and CEO and a director of Rockwell Medical, sold 6,926 shares of Rockwell Medical common stock on 10/01/2025 at a reported price of $1.19 per share.
After the transaction, the filing reports Mr. Strobeck beneficially owns 330,826 shares, held directly. The sale was executed pursuant to a Rule 10b5-1 trading plan adopted May 30, 2024, and the filer offers to provide details of the number of shares and prices upon request.